Every material Form 8-K Pluri Inc. has filed with the SEC since August 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pluri Inc. entered into a partnership agreement with ZEO ScientifiX on October 26, 2026, under which ZEO would receive an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, with Pluri receiving equity in ZEO at closing. On October 27, 2026, Pluri agreed to sell 909,092 common shares and warrants to two investors for $1.0 million in total, with closing expected on or before October 30, 2026. The stock sale adds shares outstanding, and the ZEO transaction depends on closing conditions, including agreement on an operating plan.
October 26, 2026: ZEO partnership grants ZEO an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, excluding certain aesthetics, skin care, cosmetic, or veterinary uses, which ZEO may only commerci
At closing, Pluri is to receive 41% of ZEO's issued and outstanding shares plus 50 Series D Preferred shares carrying 51% of ZEO's votes
October 27, 2026: two Securities Purchase Agreements for 909,092 common shares at $1.10 per share, with warrants for an equal number of shares at $1.30 per share; closing expected on or before October 30, 2026
Pluri agreed on October 19, 2026 to sell 833,334 common shares at $1.50 each to Chutzpah Holdings LP, a partnership beneficially owned by chairman Alexandre Weinstein, the company's largest existing shareholder. The buyer also receives a warrant to purchase up to 833,334 shares at $1.65, and the $1,250,000 it paid in June 2026 as an advance is applied in full to the price, so no further payment is due at closing. The securities are unregistered, so they cannot be offered or sold in the United States without registration or an exemption.
Shares priced at $1.50 each; warrant covers up to 833,334 shares at a $1.65 exercise price
$1,250,000 advance paid June 16, 2026 is applied in full; no additional payment due at closing
Warrant becomes exercisable on the six-month anniversary of issue and expires on the fifth anniversary of the initial exercise date
Sold without SEC registration under Section 4(a)(2) and Regulation S; agreement signed October 19, 2026
Pluri Inc. agreed on August 26, 2026, to sell 1,200,000 common shares and pre-funded warrants for up to 1,028,940 shares in a registered direct offering, with a concurrent private placement of common warrants for 2,228,940 shares. The offering is expected to close on August 28, 2026, with estimated net proceeds of about $2,984,808 for corporate development, general purposes and working capital. The sale adds shares and warrant exercise rights that could dilute existing shareholders.
Shares priced at $1.50 each; pre-funded warrants priced at $1.49999 with a $0.00001 exercise price
Common warrants exercisable at $1.65 per share, initially six months after issuance, for five years
Placement agent A.G.P./Alliance Global Partners receives a 6.50% cash fee on gross proceeds
Directors and executive officers and the company face 45-day restrictions on new share issuances and sales
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pluri Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →